{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T05:43:01Z","timestamp":1782366181748,"version":"3.54.5"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The ACOSOG Z11102 trial demonstrated the safety of breast-conserving surgery (BCS) with adjuvant radiation in women with multiple ipsilateral breast cancer (MIBC) undergoing upfront surgery, reporting a 5-year local recurrence (LR) of ~3%. However, the oncologic safety of BCS in women with MIBC receiving neoadjuvant systemic therapy (NST) remains uncertain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>Patients with stage I\u2013III unifocal or MIBC who underwent BCS following NST from 2016 to 2023 were identified in a prospectively maintained institutional database. MIBC was defined preoperatively as the presence of 2\u20133 foci of biopsy-proven breast cancer with at least 2 cm of intervening normal breast tissue and at least one focus of invasive disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 1515 patients were identified: 73 (4.8%) with MIBC and 1442 (95.2%) with unifocal disease. Baseline clinicopathologic characteristics were similar between groups. Median age was 55 years, and most received neoadjuvant chemotherapy (82.2% vs. 83.4%). Molecular subtype distribution was similar between cohorts (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.97). Of the patients with MIBC, 48 (65.8%) underwent single-site lumpectomy, 23 (31.5%) two-site lumpectomy, and 2 (2.7%) three-site lumpectomy. At median follow-up of 34.7 months, there was no difference in LR (1.4% vs. 3.1%,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.40), distant recurrence (5.5% vs. 4.6%,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.37), or breast cancer mortality (4.1% vs. 2.6%,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.45) between groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this retrospective analysis of women with MIBC who underwent BCS after NST, local recurrence (LR) was 1.4% at 3-year median follow-up, which was similar to patients with unifocal breast cancer. These findings suggest BCS is a safe surgical option in well-selected patients with MIBC undergoing NST.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-025-18939-6","type":"journal-article","created":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T22:01:03Z","timestamp":1767477663000},"page":"3355-3363","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Breast-Conserving Therapy for Multiple Ipsilateral Breast Cancer After Neoadjuvant Systemic Therapy"],"prefix":"10.1245","volume":"33","author":[{"given":"Monika K.","family":"Masanam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer R.","family":"Bellon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 P.","family":"Leone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Mittendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tari A.","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Kantor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,3]]},"reference":[{"issue":"16","key":"18939_CR1","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1056\/NEJMoa022152","volume":"347","author":"B Fisher","year":"2002","unstructured":"Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347(16):1233\u201341. https:\/\/doi.org\/10.1056\/NEJMoa022152.","journal-title":"N Engl J Med."},{"issue":"6","key":"18939_CR2","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1200\/JCO.1992.10.6.976","volume":"10","author":"AS Lichter","year":"1992","unstructured":"Lichter AS, Lippman ME, Danforth DN Jr, et al. Mastectomy versus breast-conserving therapy in the treatment of stage I and II carcinoma of the breast: a randomized trial at the National Cancer Institute. J Clin Oncol. 1992;10(6):976\u201383. https:\/\/doi.org\/10.1200\/JCO.1992.10.6.976.","journal-title":"J Clin Oncol."},{"issue":"16","key":"18939_CR3","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1056\/NEJMoa020989","volume":"347","author":"U Veronesi","year":"2002","unstructured":"Veronesi U, Cascinelli N, Mariani L, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002;347(16):1227\u201332. https:\/\/doi.org\/10.1056\/NEJMoa020989.","journal-title":"N Engl J Med."},{"issue":"1","key":"18939_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/0360-3016(89)90004-7","volume":"16","author":"KA Leopold","year":"1989","unstructured":"Leopold KA, Recht A, Schnitt SJ, et al. Results of conservative surgery and radiation therapy for multiple synchronous cancers of one breast. Int J Radiat Oncol Biol Phys. 1989;16(1):11\u20136. https:\/\/doi.org\/10.1016\/0360-3016(89)90004-7.","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"1","key":"18939_CR5","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1097\/00000658-199007000-00006","volume":"212","author":"JM Kurtz","year":"1990","unstructured":"Kurtz JM, Jacquemier J, Amalric R, et al. Breast-conserving therapy for macroscopically multiple cancers. Ann Surg. 1990;212(1):38\u201344. https:\/\/doi.org\/10.1097\/00000658-199007000-00006.","journal-title":"Ann Surg."},{"issue":"1","key":"18939_CR6","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/1097-0142(19930701)72:1<137::aid-cncr2820720126>3.0.co;2-e","volume":"72","author":"LD Wilson","year":"1993","unstructured":"Wilson LD, Beinfield M, McKhann CF, Haffty BG. Conservative surgery and radiation in the treatment of synchronous ipsilateral breast cancers. Cancer. 1993;72(1):137\u201342. https:\/\/doi.org\/10.1002\/1097-0142(19930701)72:1%3c137::aid-cncr2820720126%3e3.0.co;2-e.","journal-title":"Cancer."},{"issue":"6","key":"18939_CR7","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1097\/CCO.0000000000000991","volume":"35","author":"O Amato","year":"2023","unstructured":"Amato O, Guarneri V, Girardi F. Epidemiology trends and progress in breast cancer survival: earlier diagnosis, new therapeutics. Curr Opin Oncol. 2023;35(6):612\u20139. https:\/\/doi.org\/10.1097\/CCO.0000000000000991.","journal-title":"Curr Opin Oncol."},{"issue":"17","key":"18939_CR8","doi-asserted-by":"publisher","first-page":"3184","DOI":"10.1200\/JCO.22.02553","volume":"41","author":"JC Boughey","year":"2023","unstructured":"Boughey JC, Rosenkranz KM, Ballman KV, et al. Local recurrence after breast-conserving therapy in patients with multiple ipsilateral breast cancer: results from ACOSOG Z11102 (Alliance). J Clin Oncol. 2023;41(17):3184\u201393. https:\/\/doi.org\/10.1200\/JCO.22.02553.","journal-title":"J Clin Oncol."},{"key":"18939_CR9","doi-asserted-by":"publisher","unstructured":"Gnant M, Harbeck N, Thomssen C. St. Gallen\/Vienna 2017: a brief summary of the consensus discussion about escalation and de-escalation of primary breast cancer treatment. Breast Care (Basel). 2017;12(2):102\u2013107. https:\/\/doi.org\/10.1159\/000475698","DOI":"10.1159\/000475698"},{"issue":"3","key":"18939_CR10","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s10549-008-9959-7","volume":"113","author":"O Gentilini","year":"2009","unstructured":"Gentilini O, Botteri E, Rotmensz N, et al. Conservative surgery in patients with multifocal\/multicentric breast cancer. Breast Cancer Res Treat. 2009;113(3):577\u201383. https:\/\/doi.org\/10.1007\/s10549-008-9959-7.","journal-title":"Breast Cancer Res Treat."},{"issue":"31","key":"18939_CR11","doi-asserted-by":"publisher","first-page":"4971","DOI":"10.1200\/JCO.2006.07.6067","volume":"24","author":"JL Oh","year":"2006","unstructured":"Oh JL, Dryden MJ, Woodward WA, et al. Locoregional control of clinically diagnosed multifocal or multicentric breast cancer after neoadjuvant chemotherapy and locoregional therapy. J Clin Oncol. 2006;24(31):4971\u20135. https:\/\/doi.org\/10.1200\/JCO.2006.07.6067.","journal-title":"J Clin Oncol."},{"issue":"4","key":"18939_CR12","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1002\/bjs5.53","volume":"2","author":"ZE Winters","year":"2018","unstructured":"Winters ZE, Horsnell J, Elvers KT, et al. Systematic review of the impact of breast-conserving surgery on cancer outcomes of multiple ipsilateral breast cancers. BJS Open. 2018;2(4):162\u201374. https:\/\/doi.org\/10.1002\/bjs5.53.","journal-title":"BJS Open."},{"key":"18939_CR13","doi-asserted-by":"publisher","unstructured":"Balic M, Thomssen C, Gnant M, Harbeck N. St. Gallen\/Vienna 2023: Optimization of treatment for patients with primary breast cancer\u2014a brief summary of the consensus discussion. Breast Care (Basel). 2023;18(3):213\u2013222. https:\/\/doi.org\/10.1159\/000530584","DOI":"10.1159\/000530584"},{"issue":"5","key":"18939_CR14","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1159\/000450626","volume":"11","author":"X Zhou","year":"2016","unstructured":"Zhou X, Li Y. Local recurrence after breast-conserving surgery and mastectomy following neoadjuvant chemotherapy for locally advanced breast cancer\u2014a meta-analysis. Breast Care (Basel). 2016;11(5):345\u201351. https:\/\/doi.org\/10.1159\/000450626.","journal-title":"Breast Care (Basel)."},{"issue":"14","key":"18939_CR15","doi-asserted-by":"publisher","first-page":"2923","DOI":"10.1002\/cncr.31518","volume":"124","author":"A Valachis","year":"2018","unstructured":"Valachis A, Mamounas EP, Mittendorf EA, et al. Risk factors for locoregional disease recurrence after breast-conserving therapy in patients with breast cancer treated with neoadjuvant chemotherapy: an international collaboration and individual patient meta-analysis. Cancer. 2018;124(14):2923\u201330. https:\/\/doi.org\/10.1002\/cncr.31518.","journal-title":"Cancer."},{"issue":"1","key":"18939_CR16","doi-asserted-by":"publisher","first-page":"9032","DOI":"10.1038\/s41598-025-93491-7","volume":"15","author":"FP Cavalcante","year":"2025","unstructured":"Cavalcante FP, Zerwes FP, Alcantara R, et al. Oncological outcomes of breast-conserving surgery versus mastectomy following neoadjuvant chemotherapy in a contemporary multicenter cohort. Sci Rep. 2025;15(1):9032. https:\/\/doi.org\/10.1038\/s41598-025-93491-7.","journal-title":"Sci Rep."},{"issue":"12","key":"18939_CR17","doi-asserted-by":"publisher","first-page":"3541","DOI":"10.1245\/s10434-018-6702-4","volume":"25","author":"J Choi","year":"2018","unstructured":"Choi J, Laws A, Hu J, Barry W, Golshan M, King T. Margins in breast-conserving surgery after neoadjuvant therapy. Ann Surg Oncol. 2018;25(12):3541\u20137. https:\/\/doi.org\/10.1245\/s10434-018-6702-4.","journal-title":"Ann Surg Oncol."},{"issue":"1","key":"18939_CR18","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1186\/s12885-020-06955-6","volume":"20","author":"J Lin","year":"2020","unstructured":"Lin J, Lin KJ, Wang YF, Huang LH, Chen SL, Chen DR. Association of surgical margins with local recurrence in patients undergoing breast-conserving surgery after neoadjuvant chemotherapy. BMC Cancer. 2020;20(1):451. https:\/\/doi.org\/10.1186\/s12885-020-06955-6.","journal-title":"BMC Cancer."},{"issue":"7","key":"18939_CR19","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.3390\/jpm12071031","volume":"12","author":"G Atzori","year":"2022","unstructured":"Atzori G, Gipponi M, Cornacchia C, et al. \u201cno ink on tumor\u201d in breast-conserving surgery after neoadjuvant chemotherapy. J Pers Med. 2022;12(7):1031. https:\/\/doi.org\/10.3390\/jpm12071031.","journal-title":"J Pers Med."},{"issue":"2","key":"18939_CR20","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1002\/jso.26301","volume":"123","author":"MR Woeste","year":"2021","unstructured":"Woeste MR, Bhutiani N, Donaldson M, McMasters KM, Ajkay N. Evaluating the effect of neoadjuvant chemotherapy on surgical outcomes after breast conserving surgery. J Surg Oncol. 2021;123(2):439\u201345. https:\/\/doi.org\/10.1002\/jso.26301.","journal-title":"J Surg Oncol."},{"issue":"4","key":"18939_CR21","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1245\/s10434-014-4122-7","volume":"22","author":"B Ataseven","year":"2015","unstructured":"Ataseven B, Lederer B, Blohmer JU, et al. Impact of multifocal or multicentric disease on surgery and locoregional, distant and overall survival of 6,134 breast cancer patients treated with neoadjuvant chemotherapy. Ann Surg Oncol. 2015;22(4):1118\u201327. https:\/\/doi.org\/10.1245\/s10434-014-4122-7.","journal-title":"Ann Surg Oncol."},{"issue":"6","key":"18939_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2024.108266","volume":"50","author":"\u00c9 Di Lena","year":"2024","unstructured":"Di Lena \u00c9, Wong SM, Iny E, et al. Oncologic safety of breast conserving surgery after neoadjuvant chemotherapy in patients with multiple ipsilateral breast cancer: a retrospective multi-institutional cohort study. Eur J Surg Oncol. 2024;50(6):108266. https:\/\/doi.org\/10.1016\/j.ejso.2024.108266.","journal-title":"Eur J Surg Oncol."},{"issue":"22","key":"18939_CR23","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","volume":"376","author":"N Masuda","year":"2017","unstructured":"Masuda N, Lee SJ, Ohtani S, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017;376(22):2147\u201359. https:\/\/doi.org\/10.1056\/NEJMoa1612645.","journal-title":"N Engl J Med."},{"issue":"7","key":"18939_CR24","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa1814017","volume":"380","author":"G von Minckwitz","year":"2019","unstructured":"von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380(7):617\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1814017.","journal-title":"N Engl J Med."},{"issue":"9","key":"18939_CR25","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382(9):810\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1910549.","journal-title":"N Engl J Med."},{"issue":"11","key":"18939_CR26","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1001\/jamaoncol.2016.1897","volume":"2","author":"LM Spring","year":"2016","unstructured":"Spring LM, Gupta A, Reynolds KL, et al. Neoadjuvant endocrine therapy for estrogen receptor-positive breast cancer: a systematic review and meta-analysis. JAMA Oncol. 2016;2(11):1477\u201386. https:\/\/doi.org\/10.1001\/jamaoncol.2016.1897.","journal-title":"JAMA Oncol."},{"issue":"5","key":"18939_CR27","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.breast.2007.02.003","volume":"16","author":"S Akashi-Tanaka","year":"2007","unstructured":"Akashi-Tanaka S, Omatsu M, Shimizu C, et al. Favorable outcome in patients with breast cancer in the presence of pathological response after neoadjuvant endocrine therapy. Breast. 2007;16(5):482\u20138. https:\/\/doi.org\/10.1016\/j.breast.2007.02.003.","journal-title":"Breast."},{"issue":"11","key":"18939_CR28","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1001\/jamaoncol.2021.2132","volume":"7","author":"T Sella","year":"2021","unstructured":"Sella T, Weiss A, Mittendorf EA, et al. Neoadjuvant endocrine therapy in clinical practice: a review. JAMA Oncol. 2021;7(11):1700\u20138. https:\/\/doi.org\/10.1001\/jamaoncol.2021.2132.","journal-title":"JAMA Oncol."},{"issue":"6","key":"18939_CR29","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.ejca.2010.11.035","volume":"47","author":"NH Peters","year":"2011","unstructured":"Peters NH, van Esser S, van den Bosch MA, et al. Preoperative MRI and surgical management in patients with nonpalpable breast cancer: the MONET\u2014randomised controlled trial. Eur J Cancer. 2011;47(6):879\u201386. https:\/\/doi.org\/10.1016\/j.ejca.2010.11.035.","journal-title":"Eur J Cancer."},{"issue":"2","key":"18939_CR30","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1097\/SLA.0b013e31827a8d17","volume":"257","author":"N Houssami","year":"2013","unstructured":"Houssami N, Turner R, Morrow M. Preoperative magnetic resonance imaging in breast cancer: meta-analysis of surgical outcomes. Ann Surg. 2013;257(2):249\u201355. https:\/\/doi.org\/10.1097\/SLA.0b013e31827a8d17.","journal-title":"Ann Surg."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18939-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-18939-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18939-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T15:48:09Z","timestamp":1773330489000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-18939-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,3]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["18939"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-18939-6","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,3]]},"assertion":[{"value":"30 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JPL reports research funding from Kazia Therapeutics and Lilly and Roche. Consulting honoraria from Minerva Biotechnologies. EAM reports compensated service on scientific advisory boards for AstraZeneca, BioNTech, and Merck; uncompensated service on steering committees for Bristol Myers Squibb and Roche\/Genentech; speaker\u2019s honoraria and travel support from Merck Sharp & Dohme; and institutional research support from Roche\/Genentech (via SU2C grant) and Gilead. EAM also reports research funding from Susan Komen for the Cure for which she serves as a scientific advisor, and uncompensated participation as a member of the American Society of Clinical Oncology Board of Directors. TAK reports speaker honoraria for Exact Sciences, compensated service on the FES Steering Committee for GE Healthcare, compensated service for advisory board role for Veracyte, and compensated service as faculty for PrecisCa cancer information service","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}